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Intensive glucose lowering treatment in type 2 diabetes
The effect on microvascular disease seems to be modest at best
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The recognition that diabetes is an independent risk factor for
cardiovascular disease has led to trials of different glucose
lowering strategies in an attempt to reduce the risk of such
disease. The effect of glucose lowering on cardiovascular disease
outcomes is one of the most contentious in recent history, as
indicated by the class IIb recommendation from the joint
American Diabetes Association, American Heart Association,
and American College of Cardiology guidelines.1 In the linked
meta-analysis (doi:10.1136/bmj.d4169), Boussageon and
colleagues assess both microvascular complications and
cardiovascular events related to the intensity of glycaemic
control and the quality of randomised studies.2
Before considering individual trials several factors warrant
consideration. For example, it is possible that glucose lowering
is a much weaker intervention than previously envisaged so that
individual trials may be underpowered to detect changes in a
chosen end point. Also, current treatments may partly negate
any benefit of glucose lowering by exchanging one risk factor
for another—for example, weight gain, which has concomitant
effects on blood pressure and lipids.3
The largest study to date, which compared the effects of
intensive glucose lowering with standard treatment on
cardiovascular outcomes, reported data from five randomised
controlled trials on 33 040 patients in whom 1497 non-fatal
myocardial infarctions, 2318 coronary events, 1127 strokes,
2892 deaths, and 1391 cases of new or worsening heart failure
occurred.4 It found that a 0.9% lowering of glycated
haemoglobin ((HbA1c) 7.5% v 6.6%) was associated with a 17%
reduction in non-fatal myocardial infarctions, 15% reduction in
coronary events, and a trend towards lower stroke risk with no
statistical evidence of heterogeneity. Mortality and heart failure
did not differ significantly between intensive and standard
treatment arms. These data are consistent with literature based
analyses that excluded PROactive,5 and a meta-analysis of four
major trials with individual participant data, which also
suggested that cardiovascular benefit after intensive glucose
lowering was limited to people without known cardiovascular
disease.6
Boussageon and colleagues’ meta-analysis adds eight extra
studies with information on a further 1493 participants in whom
54 additional non-fatal myocardial infarctions, 209 deaths, and
187 cases of new or worsening heart failure occurred.2 The
cardiovascular data are broadly consistent with earlier reports,4-6
showing a 15% reduction in non-fatal myocardial infarctions
but no clear effect on other cardiovascular disease events. This
is despite inclusion of some small studies with incomplete
randomisation (UGDP), studies that lack end point adjudication
(Kumamoto study, HOME trial), and trials of agents that are
nowwithdrawn because of safety concerns (UGDP). The authors
provide sensitivity analyses based on trial quality (Jadad score
>3 for high quality v ≤3 for low quality). However, the
supposedly high quality studies provide data for only 6465
subjects with 323 non-fatal myocardial infarctions and 195
strokes, thereby reducing the available data by more than 80%.
Also the sensitivity analysis of intensive glucose lowering and
heart failure events is dominated by the PROactive study, in
which pioglitazone was the active treatment under investigation.7
It seems unlikely that there would be any clear significant
difference between low and high quality studies for the various
cardiovascular outcomes on the basis of conventional statistical
interaction analyses.
The meta-analysis is consistent with earlier evidence that the
cardiovascular benefit of intensive glucose lowering seems to
be modest at best, and that glucose lowering is probably less
efficacious and more difficult to achieve than lipid lowering
and blood pressure control (figure). A combined approach that
targets glucose lowering, lipid lowering, and blood pressure
control seems to be most beneficial,8 and available data also
suggest a long lasting beneficial effect on diabetes related
clinical events many years after an intensive regimen.9 The
authors rightfully say that an improvement in surrogate markers
(such as HbA1c) is not conclusive evidence of clinical benefit.
This was highlighted by the Food and Drug Administration in
guidance published in December 2008, which includes specific
targets for investigators to satisfy the cardiovascular safety of
new glucose lowering drugs.10
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Absolute number of events prevented by different
interventions per 1000 patient years of treatment (data
taken from Cholesterol Treatment Trialists’ Collaboration
and Blood Pressure Lowering Treatment Trialists’
Collaboration)
Boussageon and colleagues’ study provides large scale
quantification of the effect of intensive glucose lowering on
microvascular disease.2 Intensive glucose lowering reduced new
or worseningmicroalbuminuria, with a trend towards a reduction
in new or worsening retinopathy, but it had little effect on other
end points. The fact that many of the analyses are dominated
by ADVANCE11 suggests that there is considerable
heterogeneity in the definitions of microvascular end points
between trials. Nonetheless, it again seems that any effect of
intensive glucose lowering on microvascular disease is modest,
at best. The data also confirm a doubling in serious
hypoglycaemic events in patients receiving intensive treatment,
as previously documented,4 but the link between treatment,
severity of hypoglycaemia, and cardiovascular outcomes remains
unresolved.12
Clinicians should consider these benefits and risks carefully
because the most sensible treatment strategy will vary
substantially between patients. Further studies are needed to
determine whether an absolute HbA1c target should be
established for everyone or whether HBA1c should be reduced
by a target percentage from baseline, so that benefits and harms
can be balanced.
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